Treatment of hyperandrogenism in women

References

• Rabe T., Grunwald K., Runnebaum B. Differentialdiagnostische Abklärung and-rogenbedingter Krankheitsbilder. Diagnostik und Therapie von Androgenisirungserscheinungen bei der Fran, M. Breckwoldt. Diesbach Verlag, Berlin 1992; 24–90
   Google Scholar
• Grunwald K., Rabe T., Runnebaum B. Das Syndrom der Polyzystischen ovanen: Ätiologie und Pathogenese. Sterilität 1993; 9: 152–60
   Google Scholar
• Schindler. Bedeutung der Antiandrogene bci der Regulation der Ovarfunktion. Diagnsotik und Therapie von Androgenisirungserscheinungen bei der Frau, M. Breck-Woldt. Diesbach Verlag, Berlin 1992; 162–8
   Google Scholar
• Moltz. Therapie der Hypcrandrogenämie. Aktuelle Hormontherapie in der Gynäkologie, T. Kiesel Rabe, B. Runnebaum. Zuckschwerdt München, Bern, Wien, New York 1993; 545–54
   Google Scholar
• Bruchowsky N. Molekulare Wirkung von Androgenen und Antiandrogenen. Androgenisirungserscheinungen bei der Frau, S7–21, J. Hammerstein, U. Lachnit-Fixson, F. Neumann, G. Plewig. Excerpta Medica, Amsterdam 1979
   Google Scholar
• Krieg M. Molekulare Wirkung der Androgene und Antiandrogene. Diagnostik und Therapie von Androgenisirungserscheinungen bei der Frau, Breckwoldt. Diesbach Verlag, Berlin 1992; 1–11
   Google Scholar
• Neumann F., Schleusener A., Hümpel M. Antiandrogene. Gynäkologie 1979; 12: 228–42
   Google Scholar
• Hammerstein J., Meckies J., Leo-Rossenberg I., Moltz L., Zielske F. Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism. J. Steroid Biochem. 1975; 6: 827–36
   PubMedGoogle Scholar
• Neumann F. Pharmakologische Aspekte von Cyproteronacetat. Antiandrogen-Östrogentherapie bei Androgenisirungserscheinungen, S23, A. E. Schindler. de Gruyter, Berlin, New York 1988
   Google Scholar
• Girard Y., Baumann Y. B., Graf S., Hees G., Van Rosenthal M. Assessment of ACTH-adrenal activity after treatment with a glucocorticoid and an antiandrogenic steroid. Arch. Toxicol. 1979; 2: 85–92
   Google Scholar
• Fanta D. Klmische und experimentelle Grundlagen zur Hormontherapie. Akne, S1–95, D. Fanta. Springer, Wien, New York 1978
   Google Scholar
• Moltz L., Haase F., Schwartz U., Hammerstein J. Die Behandlung androgenisierter Frauen mit intramuskulär applizierbarem Cyproteronacetat. Geburtshilfe Frauenheilkd. 1983; 43: 281–7
   Google Scholar
• Moltz L., Meckies J., Hammerstein J. Die kontrazeptive Betreuung androgenisicrter Frauen mit einem niedrig dosierten cyproteronacetathaltigen Einphasenpräparat. Dtsch Med. Wochcnschr. 1979; 104: 1376–82
   PubMed Web of Science ®Google Scholar
• Döring H. F., Ilgner M. Die Behandlung mittelschwerer Virilisierungserscheinungen der Frau mit Diane und Androcur-10. Zentralbl. Hautkr. 1982; 58: 761–7
   Google Scholar
• Kotrajaras R. Comparative study in the treatment of acne vulgaris with cyproterone acetate, tetracycline and vitamin A acid. J. Med. Assoc. Thai. 1982; 65: 198–202
   Google Scholar
• Greenwood R., Brummitt L., Burke B., Cunliffe W. G. Acne: double-blind clinical and laboratory trial of tetracycline, estrogen—cyproterone acetate and combined treatment. Br. Med. J. 1985; 291: 1231–5
   PubMed Web of Science ®Google Scholar
• Belisle S., Love E. J. Clinical efficacy and safety of cyproterone acetate in severe hirsutism: results of a multicentered Canadian study. Fertil. Steril. 1986; 46: 1015–20
   PubMed Web of Science ®Google Scholar
• Carlborg L. Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Acta Obstet. Gynecol, Scand. Suppl. 1986; 134: 29–32
   PubMedGoogle Scholar
• Porcile A., Gallardo E. Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives. Fertil. Steril. 1991; 55: 877–81
   PubMed Web of Science ®Google Scholar
• O'Brian R. C., Cooper M. E., Murray R. M. L., Seeman E., Thomas A. K., Jerums G. Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism. J. Clin. Endocrinol. Metab. 1991; 72: 1008–13
   Google Scholar
• Wishart J. M. An open study of Triphasil and Diane-50 in the treatment of acne. Austr. J. Dermatol. 1991; 32: 51–4
   Google Scholar
• Lunde O., Djoseland O. A comparative study of Aldactone and Diane in the treatment of hirsutism. J. Steroid Biochem. 1987; 28: 161–5
   Google Scholar
• Colver G. B., Mortimer P. S., Dawber R. P. R. Cyproterone acetate and two doses of oestrogen in female acne; a double-blind comparison. Br. J. Dermatol. 1988; 118: 95–9
   PubMed Web of Science ®Google Scholar
• Nürnberger F. Comparison of Diane-35 with Neo-Eunomin from the dermatological viewpoint. Antiandrogen—Estrogen Therapy for Signs of Androgenization. New Developments in Biosciences, A. E. Schindler. de Gruyter, Berlin, New York 1989; 197–206
   Google Scholar
• Aydinlik S., Lachnit-Fixson U., Lehnert J. Östrogen-reduzierter Ovulationshemmer zur Aknetherapie. Doppelblindstudie zum Vergleich Diane-35 gegen Dune. Fortschr. Med. 1986; 104: 27–8
   Google Scholar
• Williamson P., Kligman A. M. A new method of the quantitative investigation of cutaneous bacteria. J. Invest. Dermatol. 1965; 45: 498–503
   PubMed Web of Science ®Google Scholar
• Lorenzo E. M. Familial study of hirsutism. J. Clin. Endocrinol. Metab. 1970; 31: 556–60
   PubMed Web of Science ®Google Scholar
• Kaiser E. Wirkung eines neuen hormonlen Kontrazeptivum (Neo-Eunomin bei Frauen mit androgenisierungserscheinungen. Geburtshilfe Frauenheilkd. 1984; 44: 651–5
   Google Scholar
• Epple R. Wie erfolgreich ist die zweistufige Behandlung mit Äthinylöstradiol-Chlormadinonazetat bei Seborrhoe, Akne und Haarausfall der Frau. Gyne 1986; 5: 1–4
   Google Scholar
• Balmer J. A., Engler F. Aknebehandlung bei Frauen—mit Neo-Eunomin. Ars. Medici. 1994; 2: 120–4
   Google Scholar
• Grunwald K., Rabe T., Runnebaum B. Hyperandrogenämie und Sterilität. Fertilität. 1994; 3: 159–69
   Google Scholar
• Hoffmann E., Meiers H. G., Hubbes A. Wirkung von antikonzeptiva auf alopezia androgenetica, seborrhoea oleosa, akne vulgaris und hirsutismus. Dtsch. Med. Wochenschr. 1974; 99: 2151–7
   Google Scholar
• Corvol P., Michaud A., Menard J., Freifeld M., Mahoudeau J. Antiandrogenic effect of spirolactones: mechanism of action. Endocrinology 1975; 97: 52–8
   PubMed Web of Science ®Google Scholar
• Menard R. H., Stripp B., Gillette J. R. Spironolactone and testicular cytochrome P-450: decreased testosterone formation in several species and changes in hepatic drug metabolism. Endocrinology 1974; 94: 1628–36
   PubMed Web of Science ®Google Scholar
• Sciarra F., Toscano V., Concolino G., Di Silverio F. Antiandrogens: clinical applications. J. Steroid Biochem. Molec. Biol. 1990; 37: 349–62
   Google Scholar
• Grunwald K., Rabe T., Schlereth G., Runnebaum B. Serumhormone vor und unter Therapie mit Cyproteronazetat und Spironolacton bei Patientinnen mit Androgenisierungserscheinungen. Geburtshilfe Frauenheilkd. 1994; 54: 634–45
   Google Scholar
• Shapiro G., Evron S. A novel use of spironolactone: treatment of hirsutism. J. Clin. Endocrinol. Metab. 1980; 51: 429–32
   PubMed Web of Science ®Google Scholar
• Tremblay R. R. Treatment of hirsutism with spironolactone. Clin. Endocrinol. Metab. 1986; 72: 1008–13
   Google Scholar
• Falaschi P., Rocco A., Del Pozo E. Inhibitory effect of bromocriptine treatment on luteinizing hormone secretion in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 1986; 62: 348–51
   Google Scholar
• Lachnit-Fixson U., Kaufmann J. Zur Beeinflussung von Androgenisierungserscheinungen-Doppelblindstudie eines cyproteronhaltigen Praeparates (SHB 209 AB) gegen Neogynon. Med. Klin. 1977; 72: 1922–6
   Google Scholar
• Messina M., Manieri C., Biffignandi P., Massucchetti C., Novi R. F., Molinatti G. M. Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism. J. Endocrinol. Invest. 1983; 6: 23–7
   Google Scholar
• Boisselle A., Tremblay J. New therapeutic approach to the hirsute patient. Fertil. Steril. 1979; 32: 276–82
   Google Scholar
• Toscano V., Casili D., Maroder M., Adamo M. V., Balducci R., Sciarra F. Cyproterone acetate (CPA) and spironolactone (SPL): effects of short-term administration in hirsute women. J. Steroid Biochem. 1985; 23: 348–53
   Google Scholar
• Ylöstalo P., Heikkinen J., Kauppila A., Pakarinen A., Järvinen P. A. Low-dose spironolactone in the treatment of female hirsutism. Int. J. Fertil. 1987; 32: 41–5
   PubMedGoogle Scholar
• Muhlemann M. F., Carter G. D., Cream J. J., Wise P. Oral spironolactone: an effective treatment for acne vulgaris in women. Br. J. Dermatol. 1986; 115: 227–32
   PubMed Web of Science ®Google Scholar
• Köksal A., Pabuccu R., Akyürek C. Spironolactone in the treatment of hirsutism. Arch. Gynecol 1987; 240: 95–100
   Google Scholar
• Goodfellow A., Alaghband-Zadeh J., Carter G., Cream J. J., Holland S., Scully J., Wise P. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br. J. Dermatol. 1984; 111: 209–14
   PubMedGoogle Scholar
• Dorrington-Ward P., McCartney A. C. E., Holland S., Scully J., Carter G., Alaghband-Zadeh J., Wise P. The effect of spironolactone on hirsutism and female androgen metabolism. Clin. Endocrinol. 1985; 23: 161–7
   PubMedGoogle Scholar
• Messina M., Manieri C., Rizzi G., Gentile L., Milani P. Treating acne with antiandrogens: the confirmation of the validity of a percutaneous treatment with spironolactone. Curr. Ther. Res. 1985; 38: 269–82
   Web of Science ®Google Scholar
• Chapman M. G., Katz M., Dowsett M., Hague W., Jeffcoate S. L., Dewhurst C. J. Spironolactone in the treatment of hirsutism. Acta Obstet. Gynecol. Scand. 1986; 65: 349–50
   Web of Science ®Google Scholar
• Beksac M. S., önderoglu L. S., Atac B. Idiopathic hirsutism with spironolactone. Fertil. Steril. 1985; 42: 216–20
   Google Scholar
• Erenus M., Gürbüz O., Durmusoglu F., Demircay Z., Pekin S. Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism. Fertil. Steril. 1994; 61: 613–16
   PubMed Web of Science ®Google Scholar
• Cusan L., Dupont A., Gomez J.-L., Tremblay R. R., Labrie F. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil. Steril. 1994; 61: 281–7
   PubMed Web of Science ®Google Scholar
• Burke B. M., Cunliffe W. J. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Brit. J. Dermatol. 1982; 112: 124–5
   Google Scholar
• Neri R. O., Florance K., Koziel P., Van Cleave S. A biological profile of a nonsteroidal antiandrogen SCH 13521 (4′-nitro-3′-trifluoromethylisobutyranilide). Endocrinology 1972; 91: 427–33
   PubMed Web of Science ®Google Scholar
• Peats E. A., Henson M. F., Neri R. On the mechanism of the antiandrogenic action of flutamide in the rat. Endocrinology 1974; 94: 532–8
   Google Scholar
• Geller J., McCoy K. Biological and biochemical effects of antiandrogen on rat ventral prostate. Acta Endocrinol. (Copenh.) 1974; 75: 385–91
   Google Scholar
• Mainwaring W. I. P., Mangan F. R., Feherty P. A., Freifeld M. An investigation into the anti-androgenic properties of the nonsteroidal compound SCH 13521 (4′-nitro-3′-trifluoromethylisobutyranilide). Mol. Cell. Endocrinol. 1974; 1: 113–18
   Google Scholar
• Callaway T. W., Bruchowsky N., Rennie P. S., Commears T. Mechanisms of action of androgens and antiandrogens: effects of antiandrogens on translocation of cytoplasmatic androgen receptor and nuclear abundance of dihydrotcstosterone. Prostate 1982; 3: 599–603
   Google Scholar
• Wysowski D. K., Frieman P., Tourtelot J. B., Horton M. L. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann. Intern. Med. 1993; 118: 860–4
   PubMed Web of Science ®Google Scholar
• Moller S., Iversen P., Franzmann M. B. Flutamide-induced liver failure. J. Hepatol. 1990; 10: 346–9
   PubMedGoogle Scholar
• Gomez J. L., Dupont A., Cusan L., Tremblay M., Suburu R., Lemay M. Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am. J. Med. 1992; 92: 465–70
   PubMed Web of Science ®Google Scholar
• Faich G. A. Adverse-drug reaction monitoring. N. Engl. J. Med. 1986; 314: 1589–92
   PubMed Web of Science ®Google Scholar
• Crawford E. D., Eisenberger M. A., McLeod D. G. A controlled trial of leuprolide with and without flutamide in prostatic cancer. N. Engl. J. Med. 1989; 321: 421–4
   Google Scholar
• Iverson P., Wolf H., Hvidt V., Krarup T., Rasmussen F., Danish Prostate Cancer Group. Zoladex plus flutamide vs. orchiectomy in the treatment of advanced prostatic cancer. J. Urol. 1989; 141, abstr., 348
   Google Scholar
• Lund F., Rasmussen F. Flutamide versus stilbestrol in the management of advanced prostatic cancer. A controlled prospective study. Br. J. Urol. 1988; 61: 140–2
   PubMedGoogle Scholar
• Keating M. A., Griffin P. P., Schiff S. F. Flutamide in the treatment of advanced prostate cancer. J. Urol. 1986; 135, abstr. 203
   Google Scholar
• Fruzzetti F., De Lorenzo D., Ricci C., Fioretti P. Clinical and endocrine effects of flutamide in hyperandrogenetic women. Fertil. Steril. 1993; 60: 806–13
   PubMed Web of Science ®Google Scholar
• Tremblay R. R. Compromise in the treatment of hirsutism with flutamide. In Vivo 1993; 7: 549–52
   Google Scholar
• Motta T., Maggi G., Perra M., Azzolan E., Casazza S., D'Alberton A. Flutamide in the treatment of hirsutism. Int. J. Gynecol. Obstet. 1991; 36: 155–7
   PubMed Web of Science ®Google Scholar
• Couzinet B., Phoisena M., Young J., Schalson G. The impact of a pure anti-androgen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism. Clin. Endocrinol. 1993; 39: 157–62
   PubMed Web of Science ®Google Scholar
• Vitale F., Ruggieri P. Flutamide: a rational approach to hirsutism. Acta Eur. Fertil. 1992; 23: 33–5
   Google Scholar
• Marcondes J. A. M., Minnani S. L., Luthold W. W., Wajchenberg B. L., Samojhk E., Kirschner M. A. Treatment of hirsutism in women with flutamide. Fertil. Steril. 1992; 57: 543–7
   PubMed Web of Science ®Google Scholar
• Cusan L., Dupont A., Belanger A., Tremblay R. R., Manhes G., Labne F. Treatment of hirsutism with the pure antiandrogen flutamide. J. Am. Acad. Dermatol. 1990; 23: 462–9
   PubMed Web of Science ®Google Scholar
• Tiiltinen A., Simberg N., Stenman U. H., Ylikorkola O. Estrogen replacement does not potentiate gonadotropm-releasing hormone agonist-induced androgen suppression in treatment of hirsutism. J. Clin. Endocrinol. Metab. 1994; 79: 447–51
   Google Scholar
• Adashi E. Y. Potential utility of gonadotropin-releasing hormone agonist in the management of ovarian hyperandrogcnism. Fertil. Steril. 1990; 53: 765–79
   PubMed Web of Science ®Google Scholar
• Rademaker M., Simpson N. B., Gudmundsson J., Bonduelle M., Fleming R., Coutts J. R. T. Effect of the gonadotropin-releasing hormone analogue, goserelm, and oestradiol replacement on sebum secretion rates and hair size in mildly hirsute women. J. Dermatol. Treat. 1991; 1: 289–92
   Google Scholar
• Carmma E., Janni A., Lobo R. Physiological estrogen replacement may enhance the effectiveness of the gonadotropin-releasing hormone agonist in the treatment of hirsutism. J. Clin. Endocrinol. Metab. 1994; 78: 126–30
   Google Scholar
• Morcos R. N., Abdul-Malak M. E., Shikora E. Treatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy. Fertil. Steril. 1994; 61: 427–31
   PubMed Web of Science ®Google Scholar
• Rittmaster R. S., Thrompson D. L. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: The relative importance of the ovary and the adrenal in the pathogenesis of hirsutism. J. Clin. Endocrinol. Metab. 1990; 70: 1096–102
   PubMed Web of Science ®Google Scholar
• Crosby P. D. A., Rittmaster R. S. Predictors of clinical response in hirsute women treated with spironolactone. Fertil. Steril. 1991; 55: 1076–81
   Google Scholar
• Wallace C., Lalor E. A., Chik C. C., Wisowski D. K., Fourcroy J. L. Hepatatoxicity complicating flutamide treatment of hirsutism. Ann. Intem. Med. 1993; 119: 1150–5
   Google Scholar
• Strauss J. S., Kligman A. M., Pochi P. E. The effect of antiandrogens and estrogens on human sebaceous glands. J. Invest. Dermatol. 1962; 39: 139–55
   PubMed Web of Science ®Google Scholar
• Winkler. Hormonbehandlung in der Dermatologie. de Gruyter, Berlin 1969
   Google Scholar
• Plewig G., Kligman A. Akne: Pathogenese, Morphologie, Therapie. Springer, Berlin, Heidelberg, New York 1978
   Google Scholar
• Sansonc G., Reisner R. M. Differential rates of conversion of testosterone to dihydrotestosterone in acne and normal human skin: a possible pathogenic factor in acne. J. Invest. Dermatol. 1971; 56: 366–72
   Google Scholar
• Fanta D., Schneider W. H. F., Spona J., Neufeld T. Die Anwendung von antiandrogenen in der Behandlung der Akne. Wien Klin. Wochcnschr. 1977; 89: 622–7
   PubMed Web of Science ®Google Scholar
• Meinhof W., Kaiser E., Loch E. G. Die androgenetische Akne der Frau. Hautarzt 1974; 25: 34–8
   Google Scholar
• Aydinlik. Von Diane zu Diane-35. Diagnostik und Therapie von Androgenisirungserscheinungen bei der Frau, Breckwoldt. Diesbach Verlag, Berlin 1992; 154–62
   Google Scholar
• Fanta. Hormonale und nichthormonale Therapie der acne vulgaris. Diagnsotik und Therapie von Androgenisirungserscheinungen bei der Frau, M. Breckwoldt. Diesbach Verlag, Berlin 1992; 136–40
   Google Scholar
• Monk B. E., Almeyda J. A., Caldwell I. W., Green B., Pelta D., Leonard J., Du Vivier A., Johnson K., Tolowinska I. Efficacy of low-dose cyproterone acetate compared with minocycline in the treatment of acne vulgaris. Clin. Exp. Dermatol. 1987; 12: 319–22
   Google Scholar
• Moltz L. Differenzierter Einsatz von Cyproteronacetat Bei Verscheidenen Androgenbedingten Krankheitsbieden der Frau. Diagnostik und Therapie von Androgenisirungserscheinungen bei der Frau, M. Breckwoldt. Diesbach Verlag, Berlin 1992; 154–61
   Google Scholar
• De Villez R. L. Topical Minoxidil therapy in hereditary androgenetic alopecia. Arch. Dermatol. 1985; 121: 197–202
   PubMedGoogle Scholar
• Klobusch J., Mossier K., Rabe T., Runnebaum B. Neue Ansätze in der Diagnostik und Therapie der Alopezie in der Gynäkologie. Therapeutische Umschau. 1990; 47: 985–90
   Google Scholar
• Mossier K. Thymu-Skin R: neuer Therapieansatz bei der Behandlung der alopecia androgenetica und der alopecia areata. Der. Deutsche. Dermatologe. 1991; 7: 3–10
   Google Scholar
• Wysowski D. K., Fourcroy J. L. Response to Wallace, C. and Lalor, E. A; Hepatotoxicity complicating flutamide treatment of hirsutism. Ann. Intern. Med. 1993; 119: 1150
   Google Scholar
• Neuman I., Thierau D., Andrae U., Greim H., Schwarz L. R. Cyproterone acetate induces DNA damage in cultured rat hepatocytes and preferentially stimulates DNA synthesis in Y-glutamyltranspeptidase-positive cells. Carcinogenesis 1992; 13: 373–8
   PubMed Web of Science ®Google Scholar
• Topinka J., Andrae U., Schwarz L. R., Werner S., Schramm R. J., Wolff T. Persistence and accumulation of DNA adducts by the synthetic steroid cyproterone acetate in rat liver in vivo. Abstract of a poster presented at the 23rd Annual Meeting of the European Environmental Mutagen Society (EEMS) in Barcelona. Sept/Oct, 1993
   Google Scholar
• Martelli A., Ghia M., Mattioli F., Mereto E., Andrae U. Experimental evidence for a carcinogenic risk of cyproterone acetate to humans (Poster). Presented at 27th Congresso Nationale Di Farmacologia, Turin, September, 1994
   Google Scholar
• Ohri S. K., Caer J. A. R., Keane P. F. Hepatocellular carcinoma and treatment with cyproterone acetate. Br. J. Urol. 1991; 67: 213–21
   Google Scholar
• Watanabe S., Yamasaki S., Tanac A., Hisi I., Honna T. Three cases of hepatocellular carcinoma among cyproterone users. Lancet 1994; 344: 1567–8, ad hoc committee on Androcur users
   PubMed Web of Science ®Google Scholar
• Rabe T., Feldmann K., Grunwald K., Runnebaum B. Liver tumors in women on oral contraceptives. Lancet 1994; 344: 1568–9
   Google Scholar